Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy [PDF]
, 2016 Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
et al,, Park, Haeseong
core +5 more sources
New England Journal of Medicine, 1979 During the past two decades, new approaches to the diagnosis and treatment of Hodgkin's disease have contributed to improved rates of survival and probable cure. Currently, patients with Hodgkin's disease are treated according to the stage and symptoms of their disease.
Anthony T. Piro +2 more
openaire +6 more sources
Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma. [PDF]
, 2020 Introduction: the high cure rates achieved in early-stage (ES) Hodgkin lymphoma (HL) are one of the great successes of hemato-oncology, but late treatment-related toxicity undermines long-term survival.
Barrington, SF +11 more
core +2 more sources
Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year followup in the West of Scotland Cancer Network [PDF]
, 2011 Clinically and biologically, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has much more in common with germinal-center derived B-cell non-Hodgkin lymphoma (NHL) than with classical Hodgkin lymphoma (cHL).
Diehl V +8 more
core +1 more source
Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma : endpoints of a spectrum of one disease? [PDF]
, 2013 In contrast to the commonly indolent clinical behavior of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), T cell/histiocyte rich large B cell lymphoma (THRLBCL) is frequently diagnosed in advanced clinical stages and has a poor prognosis ...
Döring, Claudia +13 more
core +3 more sources
Human leukocyte antigens and genetic susceptibility to lymphoma [PDF]
, 2015 Familial aggregation, coupled with ethnic variation in incidence, suggests that inherited susceptibility plays a role in the development of lymphoma, and the search for genetic risk factors has highlighted the contribution of the human leukocyte antigen (
Jarrett, R.F., McAulay, K.A.
core +1 more source
GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers [PDF]
, 2012 Background: Increased glycolytic activity is a hallmark of cancer, allowing staging and restaging with 18F-fluorodeoxyglucose-positron-emission-tomography (PET).
Agostinelli, Claudio +9 more
core +1 more source
Paediatrica Indonesiana, 2017 A case of Hodgkin's disease in an 8-year-old Indonesian boy is presented. The treatment was stanted 2½ years after the first onset of the symptoms,consisting of vincristine, cyclophosphamide and prednisone. It seemed that this combination gave good results; after 12 weeks of treatment the lymphnodes disappeared and no new swellings developed.
Inda D. Arif +2 more
openaire +4 more sources
Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma [PDF]
, 2016 Levels of plasma cell-free DNA (cfDNA) of a large series of children with classical Hodgkin lymphoma (cHL) were evaluated and analyzed at diagnosis and during chemotherapy treatment in relation with clinical characteristics.
Basso, Giuseppe +11 more
core +2 more sources
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study. [PDF]
, 2019 PURPOSE: Accurate stratification of patients is an important goal in Hodgkin lymphoma (HL), but the role of pretreatment clinical risk stratification in the context of positron emission tomography (PET) -adapted treatment is unclear.
Barrington, SF +14 more
core +3 more sources